Last reviewed · How we verify

Gemcitabine (GEM) — Competitive Intelligence Brief

Gemcitabine (GEM) (Gemcitabine (GEM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog; antimetabolite. Area: Oncology.

marketed Nucleoside analog; antimetabolite Ribonucleotide reductase; DNA polymerase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine (GEM) (Gemcitabine (GEM)) — Sun Yat-sen University. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Gemcitabine (GEM) TARGET Gemcitabine (GEM) Sun Yat-sen University marketed Nucleoside analog; antimetabolite Ribonucleotide reductase; DNA polymerase
Gemcitabine alone Gemcitabine alone Intergroupe Francophone de Cancerologie Thoracique phase 3 Nucleoside analog antimetabolite Ribonucleotide reductase; DNA polymerase
Chemotherapy, gemcitabine Chemotherapy, gemcitabine University of Erlangen-Nürnberg Medical School phase 3 Nucleoside analog; antimetabolite chemotherapy Ribonucleotide reductase; DNA polymerase
Chemotherapy,Gemcitabine based regimen Chemotherapy,Gemcitabine based regimen Eye & ENT Hospital of Fudan University phase 3 Nucleoside analog; antimetabolite chemotherapy Ribonucleotide reductase; DNA polymerase
clofarabine, fludarabine and busulfan, CloFluBu clofarabine, fludarabine and busulfan, CloFluBu Vastra Gotaland Region phase 3 Chemotherapy combination (nucleoside analogs + alkylating agent) DNA synthesis and repair pathways; ribonucleotide reductase; DNA polymerase
Fludarabine mono Fludarabine mono German CLL Study Group phase 3 Purine analog antimetabolite Ribonucleotide reductase; DNA polymerase
Biktarvy BICTEGRAVIR Gilead Sciences marketed Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Nucleoside analog; antimetabolite class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  2. Astellas Pharma Global Development, Inc. · 1 drug in this class
  3. AstraZeneca · 1 drug in this class
  4. Celgene · 1 drug in this class
  5. Centre Hospitalier Universitaire Dijon · 1 drug in this class
  6. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
  7. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
  8. Eisai Inc. · 1 drug in this class
  9. Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
  10. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine (GEM) — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-gem. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: